Dissecting the nuances of cancer epigenomics in liquid biopsy

References

• 1. McGranahan N, Swanton C. Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future. Cell 168(4), 613–628 (2017).
  Medline CASGoogle Scholar
• 2. Rolfo C, Mack P, Scagliotti GV et al. Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer. J. Thorac. Oncol. 16(10), 1647–1662 (2021).
  Medline CASGoogle Scholar
• 3. Gristina V, Barraco N, La Mantia M et al. Clinical Potential of Circulating Cell-Free DNA (cfDNA) for Longitudinally Monitoring Clinical Outcomes in the First-Line Setting of Non-Small-Cell Lung Cancer (NSCLC): A Real-World Prospective Study. Cancers (Basel) 14(23), 6013 (2022).
  Medline CASGoogle Scholar
• 4. Russo A, Incorvaia L, Del Re M et al. The molecular profiling of solid tumors by liquid biopsy: a position paper of the AIOM–SIAPEC-IAP–SIBioC–SIC–SIF Italian Scientific Societies. ESMO Open 6(3), 100164 (2021).
  Medline CASGoogle Scholar
• 5. Bettegowda C, Sausen M, Leary RJ et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci. Transl. Med. 6(224), 224ra24 (2014).
  MedlineGoogle Scholar
• 6. Reichert ZR, Morgan TM, Li G et al. Prognostic value of plasma circulating tumor DNA fraction across four common cancer types: a real-world outcomes study. Ann. Oncol. 34(1), 111–120 (2023).
  Medline CASGoogle Scholar
• 7. Fan S, Chi W. Methods for genome-wide DNA methylation analysis in human cancer. Brief. Funct. Genomics 15(6), 432–442 (2016).
  Medline CASGoogle Scholar
• 8. Warton K, Samimi G. Methylation of cell-free circulating DNA in the diagnosis of cancer. Front. Mol. Biosci. 2, 13 (2015).
  MedlineGoogle Scholar
• 9. Lamb YN, Dhillon S. Epi proColon^® 2.0 CE: A Blood-Based Screening Test for Colorectal Cancer. Mol. Diagnosis Ther. 2, 225–232 (2017).
  Google Scholar
• 10. Gristina V, La Mantia M, Peri M et al. Navigating the liquid biopsy Minimal Residual Disease (MRD) in non-small cell lung cancer: making the invisible visible. Crit. Rev. Oncol. Hematol. 182, 103899 (2023).
  MedlineGoogle Scholar
• 11. Chang MT, Asthana S, Gao SP et al. Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. Nat. Biotechnol. (2), 155–63 (2016).
  MedlineGoogle Scholar
• 12. Locke WJ, Guanzon D, Ma C et al. DNA Methylation Cancer Biomarkers: Translation to the Clinic. Front. Genet. 10, 1150 (2019).
  Medline CASGoogle Scholar
• 13. Allen Chan KC, Jiang P, Chan CWM et al. Noninvasive detection of cancer-associated genomewide hypomethylation and copy number aberrations by plasma DNA bisulfite sequencing. Proc. Natl Acad. Sci. USA 110(47), 18761–18768 (2013).
  MedlineGoogle Scholar
• 14. Guo S, Diep D, Plongthongkum N, Fung HL, Zhang K, Zhang K. Identification of methylation haplotype blocks AIDS in deconvolution of heterogeneous tissue samples and tumor tissue-of-origin mapping from plasma DNA. Nat. Genet. 49, 635–642 (2017).
  Medline CASGoogle Scholar
• 15. Jensen TJ, Kim SK, Zhu Z et al. Whole genome bisulfite sequencing of cell-free DNA and its cellular contributors uncovers placenta hypomethylated domains. Genome Biol. 16(1), 78 (2015).
  MedlineGoogle Scholar
• 16. Liu MC, Oxnard GR, Klein EA et al. Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA. Ann. Oncol. 6, 745–759 (2020).
  Google Scholar
• 17. Klein EA, Richards D, Cohn A et al. Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set. Ann. Oncol. 9, 1167–1177 (2021).
  Google Scholar
• 18. Klutstein M, Nejman D, Greenfield R, Cedar H. DNA methylation in cancer and aging. Cancer Res. 76(12), 3446–50 (2016).
  Medline CASGoogle Scholar
• 19. Worm Ørntoft MB, Jensen SØ, Hansen TB, Bramsen JB, Andersen CL. Comparative analysis of 12 different kits for bisulfite conversion of circulating cell-free DNA. Epigenetics 12(8), 626–636 (2017).
  MedlineGoogle Scholar
• 20. Tanaka K, Okamoto A. Degradation of DNA by bisulfite treatment. Bioorganic Med. Chem. Lett. 17(7), 1912–5 (2007).
  Medline CASGoogle Scholar
• 21. Chemi F, Pearce SP, Clipson A et al. cfDNA methylome profiling for detection and subtyping of small cell lung cancers. Nat. Cancer 3, 1260–1270 (2022).
  Medline CASGoogle Scholar
• 22. Mouliere F, Chandrananda D, Piskorz AM et al. Enhanced detection of circulating tumor DNA by fragment size analysis. Sci. Transl. Med. 10(466), eaat4921 (2018).
  MedlineGoogle Scholar
• 23. Cristiano S, Leal A, Phallen J et al. Genome-wide cell-free DNA fragmentation in patients with cancer. Nature 570, 385–389 (2019).
  Medline CASGoogle Scholar
• 24. Ivanov M, Baranova A, Butler T, Spellman P, Mileyko V. Non-random fragmentation patterns in circulating cell-free DNA reflect epigenetic regulation. BMC Genomics 16(Suppl. 13), S1 (2015).
  MedlineGoogle Scholar
• 25. Gianni C, Palleschi M, Merloni F et al. Cell-Free DNA Fragmentomics: A Promising Biomarker for Diagnosis, Prognosis and Prediction of Response in Breast Cancer. Int. J. Mol. Sci. 23(22), 14197 (2022).
  Medline CASGoogle Scholar
• 26. Mathios D, Johansen JS, Cristiano S et al. Detection and characterization of lung cancer using cell-free DNA fragmentomes. Nat. Commun. 12, 5060 (2021).
  Medline CASGoogle Scholar
• 27. Foda ZH, Annapragada AV, Boyapati K et al. Detecting Liver Cancer Using Cell-Free DNA Fragmentomes. Cancer Discov. 13(3), 616–631 (2023).
  Medline CASGoogle Scholar